$NHWK News
Last published 2y ago
- 2y agoNHWKSCPXScorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major UniversityGlobeNewswireDURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a
- 2y agoNHWKSCPXScorpius Holdings Accepted as a Member of the US Government's BioMaP-ConsortiumGlobeNewswireDURHAM, N.C., March 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been accepted into
- 2y agoNHWKSCPXScorpius Holdings, Inc. Announces Closing of Public OfferingGlobeNewswireDURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the closing
- 2y agoNHWKSCPXScorpius Holdings, Inc. Announces Pricing of Public OfferingGlobeNewswireDURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the pricing
- 2y agoNHWKSCPXScorpius Holdings, Inc. Announces Proposed Public Offering of Common StockGlobeNewswireDURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX) ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced that it
- 2y agoNHWKSCPXScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023GlobeNewswireEstimates Sequential Reduction in the Fourth Quarter of 2023 Operating Loss by Over $3.3 Million or Approximately 30% Compared to the Third Quarter of 2023 Achieves Record Backlog of $9.3 Million DURHAM, N.C., March
- 2y agoNHWKNightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under "SCPX" Effective at the Market Open TodayGlobeNewswireDURHAM, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences / Scorpius Holdings, Inc. (NYSE American: NHWK; SCPX), an integrated contract development and manufacturing organization (CDMO), today announced
- 2y agoNHWKNightHawk's Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating OfficerGlobeNewswireDURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK) ("NightHawk" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the promotion
- 2y agoNHWKNightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing NoteGlobeNewswireDURHAM, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK) ("NightHawk" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced it has sold
- 2y agoNHWKNightHawk's Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical ProgramGlobeNewswireDURHAM, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK) ("NightHawk" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius
- 2y agoNHWKNightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientGlobeNewswireDURHAM, N.C., Jan. 16, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK) ("NightHawk" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius
- 2y agoNHWKNightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMOGlobeNewswireDURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK; NHWK), an integrated contract development and manufacturing organization (CDMO), today announced that it is changing the name
- 2y agoNHWKNightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National UniversityGlobeNewswireDURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK) ("NightHawk" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius
- 2y agoNHWKNightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research UniversityGlobeNewswireNext phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as state-of-the-art San Antonio
- 2y agoNHWKNightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical CompanyGlobeNewswireManufacturing run at Scorpius' state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing Advances multi-million dollar biomanufacturing contract awarded earlier this year; set to expand
- 2y agoNHWKNightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core AssetsGlobeNewswireOver $20 million in signed manufacturing contracts which includepremier biotech/pharma companies and research institutes Elusys divestiture and R&D cuts expected to eliminate over $40 million in commitments and
- 2y agoNHWKNightHawk Biosciences Provides Q3 2023 Business UpdateGlobeNewswireDURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of
- 3y agoNHWKNightHawk Biosciences Provides Q2 2023 Business UpdateGlobeNewswireDURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of
- 3y agoNHWKNightHawk Biosciences Provides Q1 2023 Business UpdateGlobeNewswireDURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of
- 3y agoNHWKNightHawk Biosciences Provides 2022 Year End Business UpdateGlobeNewswireDURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today
- 3y agoNHWKNightHawk Biosciences Provides Third Quarter 2022 Business UpdateGlobeNewswireDURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today
- 4y agoNHWKNighthawk Biosciences' Scorpion Subsidiary Announces Grand Opening of its San Antonio FacilityGlobeNewswireDURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today
- 4y agoNHWKNightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) LaboratoryGlobeNewswireDURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the construction of an advance
- 4y agoNHWKNightHawk Biosciences Provides Second Quarter 2022 Business UpdateGlobeNewswireDURHAM, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and opera
- 4y agoNHWKNightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological ServicesGlobeNewswireDURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Stephan Kut
- 4y agoNHWKNightHawk Biosciences Provides First Quarter 2022 Business UpdateGlobeNewswireDURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operat
- 4y agoHTBXNHWKNightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35GlobeNewswireDURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA
- 4y agoHTBXNHWKHeat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open TodayGlobeNewswireDURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today an